C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Acquires New Position in Dynavax Technologies Co. (NASDAQ:DVAX)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 5,540 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

A number of other large investors also recently modified their holdings of the company. US Bancorp DE raised its position in Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies in the 3rd quarter valued at $45,000. GAMMA Investing LLC lifted its holdings in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares during the period. Finally, KBC Group NV grew its position in Dynavax Technologies by 68.7% in the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 2,857 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DVAX has been the subject of a number of research analyst reports. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Dynavax Technologies in a report on Friday.

Dynavax Technologies Price Performance

NASDAQ:DVAX opened at $13.33 on Friday. The company has a fifty day moving average price of $12.81 and a 200 day moving average price of $11.99. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.05. The stock has a market cap of $1.75 billion, a P/E ratio of 102.55 and a beta of 1.32.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 3.19% and a net margin of 7.85%. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Analysts anticipate that Dynavax Technologies Co. will post 0.2 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.